Agios pharmaceuticals, inc. (AGIO)
Income statement / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11
Revenues:
Grant revenue

-

-

-

-

-

-

-

34

34

Total revenue

117,912

94,387

43,011

69,892

59,119

-

-

25,106

21,837

Cost and expenses:
Cost of sales

1,317

1,397

0

0

-

-

-

-

-

Research and development

410,894

341,324

292,681

220,163

141,827

100,371

54,502

41,037

31,253

Selling, general and administrative

132,034

114,145

71,124

50,714

35,992

19,120

9,929

7,064

7,215

Total cost and expenses

544,245

456,866

363,805

270,877

177,819

119,491

64,431

48,101

38,468

Loss from operations

-426,333

-362,479

-320,794

-200,985

-118,700

-54,133

-38,883

-22,995

-16,631

Interest income, net

14,861

16,451

6,124

2,514

968

203

55

69

132

Loss before income taxes

-

-

-

-

-

-53,930

-38,828

-22,926

-16,499

Benefit from income taxes

-

-

-

-

-

-426

579

-2,824

7,207

Net loss

-411,472

-346,028

-314,670

-198,471

-117,732

-53,504

-39,407

-20,102

-23,706

Cumulative preferred stock dividends

-

-

-

-

-

-

4,162

7,190

3,100

Net loss applicable to common stockholders

-

-

-

-

-

-

-43,569

-27,292

-26,806

Net loss per share – basic and diluted (in usd per share)

-6.86

-6.03

-6.75

-5.07

-3.15

-1.59

-2.83

-8.02

-8.90

Weighted-average number of common shares used in computing net loss per share – basic and diluted (in usd per share)

59,994

57,418

46,587

39,126

37,429

33,667

15,415

3,401

3,013

Product revenue, net
Total revenue

59,851

13,841

0

0

-

-

-

-

-

Collaboration revenue – related party
Total revenue

39,257

60,661

41,074

69,892

59,119

65,358

25,548

25,072

21,803

Collaboration revenue – other
Total revenue

8,262

12,670

0

0

-

-

-

-

-

Royalty revenue – related party
Total revenue

10,542

7,215

1,937

0

0

-

-

-

-